TCGA-A7-A3IY-01A-21R-A21T-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 12
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.440
- COAGULATION+0.430
- KRAS_SIGNALING_UP+0.400
- ALLOGRAFT_REJECTION+0.390
- ANGIOGENESIS+0.390
- INFLAMMATORY_RESPONSE+0.390
- PANCREAS_BETA_CELLS+0.350
- P53_PATHWAY+0.300
- COMPLEMENT+0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.290
Top 10 suppressed
- G2M_CHECKPOINT-0.470
- MITOTIC_SPINDLE-0.450
- E2F_TARGETS-0.410
- MYC_TARGETS_V2-0.310
- PI3K_AKT_MTOR_SIGNALING-0.310
- UV_RESPONSE_DN-0.120
- ADIPOGENESIS-0.110
- MYC_TARGETS_V1-0.110
- PROTEIN_SECRETION-0.110
- WNT_BETA_CATENIN_SIGNALING-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 37870efb-e4e9-4772-bdec-b9de38ce4aec | — | — | 0.894 |
| 2 | SJEPD013_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.888 |
| 3 | MDT-AP-0410 | Med | Medulloblastoma | 0.871 |
| 4 | MDT-AP-0816 | Med | Medulloblastoma | 0.863 |
| 5 | MDT-AP-0484 | Med | Medulloblastoma | 0.850 |
| 6 | ERR2598312 | fetal | fetal | 0.850 |
| 7 | MDT-AP-0499 | Med | Medulloblastoma | 0.842 |
| 8 | ERR2598287 | fetal | fetal | 0.840 |
| 9 | SRR33532823 | — | C | 0.836 |
| 10 | SAMN03290935 | — | — | 0.835 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.440 | Inavolisib | — uncovered |
| COAGULATION | 0.430 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.390 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| P53_PATHWAY | 0.300 | Idelalisib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.290 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.270 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.260 | Inavolisib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| HYPOXIA | 0.240 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.220 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.210 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.210 | Idelalisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |